Vitridinol 120 mg 56 coated tablets

Peptic ulcer disease of the stomach and duodenum in the acute phase, including that associated with Helicobacter pylori.
Chronic gastritis and gastroduodenitis in the acute phase, including that associated with Helicobacter pylori.
Functional dyspepsia not related to organic gastrointestinal diseases.
Irritable bowel syndrome predominantly presenting with diarrhea symptoms.

For oral use. The duration of treatment and dosage of the medication is determined by the attending physician individually for each patient, depending on the nature of the disease.
Adults and children over 12 years of age are prescribed 1 tablet 4 times a day 30 minutes before meals (breakfast, lunch, dinner) and at night, or 2 tablets 2 times a day 30 minutes before meals (breakfast, dinner).
Children aged 8 to 12 years are prescribed 1 tablet 2 times a day 30 minutes before meals (breakfast, dinner).
Children aged 4 to 8 years are prescribed a dose of 8 mg/kg/day; depending on the child's body weight, 1-2 tablets per day are prescribed (respectively, in 1-2 doses per day). The daily dose should be as close as possible to the calculated dose (8 mg/kg/day). Tablets are taken 30 minutes before meals, with a small amount of water.
It is recommended to swallow the tablet whole, without chewing or crushing, with a sufficient amount of water. It is not recommended to take the tablets with milk. The duration of treatment usually lasts from 4 to 8 weeks. After completing the medication, it is not recommended to take medications containing bismuth (e.g., Vikalin, Vikaire) for 2 months.
For the eradication of Helicobacter pylori, the use of bismuth potassium dicitrate in combination with antibacterial agents that have anti-Helicobacter activity is advisable.
If no improvement occurs during treatment, consult a physician. Use the medication only according to the method of administration and in the doses specified in the instructions. If necessary, please consult a physician before using the medication.

Active ingredient: bismuth potassium dicitrate - 304.6 mg, calculated as bismuth oxide Bi2O3 - 120 mg.
Excipients: corn starch - 70.6 mg, povidone K30 - 17.7 mg, potassium polyacrylate - 23.6 mg, macrogol 6000 - 6.0 mg, magnesium stearate - 2.0 mg.
Coating: dry film coating mixture - 4.3 mg, containing polyvinyl alcohol, polyethylene glycol/macrogol 3350, yellow quinoline (E 104), talc, titanium dioxide, indigo carmine (E 132).

Round biconvex coated tablets, from light yellow to yellow in color.

Increased individual sensitivity to the components of the drug;
pregnancy;
lactation period;
use of medications containing bismuth;
severe impairment of kidney function (severe renal failure (creatinine clearance less than 30 ml/min) and chronic renal failure);
children under 4 years of age.
Pregnancy and lactation:
Contraindicated during pregnancy.

During treatment, breastfeeding should be discontinued.

The medication should not be used for more than 8 weeks.
During treatment, it is not recommended to exceed the established daily doses for adults and children.
During treatment with Vitridinol®, other medications containing bismuth should not be used, as this increases the risk of systemic side effects due to elevated bismuth concentration in the blood.
The use of Vitridinol® may cause darkening of the stool due to the formation of bismuth sulfide. Occasionally, slight darkening of the tongue is noted.

Effects on the ability to drive vehicles and operate machinery:
Data on the effect of Vitridinol on the ability to drive a car and operate machinery are not available.

The side effects listed below, observed with the use of bismuth potassium dicitrate, are categorized by frequency of occurrence according to the following gradation: very common (≥1/10); common (≥1/100, < 1/10); uncommon (≥1/1000,Prolonged use of the medication in doses exceeding the recommended amounts may cause bismuth poisoning. Symptoms of poisoning: dyspepsia, rash, inflammation of the mucous membrane of the oral cavity, characteristic darkening in the form of blue lines on the gums; kidney function impairment may occur. These symptoms are fully reversible upon discontinuation of the medication. Treatment: there is no specific antidote. In case of overdose, gastric lavage, administration of enterosorbents, and symptomatic therapy aimed at maintaining kidney function are indicated. In the event of an overdose, the use of saline laxatives is also recommended. Further treatment should be symptomatic. In cases of kidney function impairment accompanied by high levels of bismuth in the plasma, chelating agents such as dimercaptosuccinic acid and dimercaptopropanesulfonic acid may be administered. In cases of severe kidney function impairment, hemodialysis is indicated.It is not recommended to take other medications orally, as well as food and liquids, particularly antacids, milk, fruits, and fruit juices, within half an hour before and after taking the medication. This is due to the fact that they may affect the effectiveness of the medication when taken simultaneously. Concurrent use of the medication with tetracyclines reduces the absorption of the latter. Alcohol should not be consumed during treatment with the medication.

Anti-ulcer agent with bactericidal activity against Helicobacter pylori. Also has anti-inflammatory and astringent effects.

In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate precipitate, forming chelate compounds with the protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, the formation of mucus, and the secretion of bicarbonate, it stimulates the activity of cytoprotective mechanisms, enhancing the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes, and bile salts. Leads to the accumulation of epidermal growth factor in the area of the defect. Reduces the activity of pepsin and pepsinogen.

Bismuth potassium dicitrate is practically not absorbed from the gastrointestinal tract. It is primarily excreted with feces. A small amount of bismuth that enters the plasma is eliminated from the body by the kidneys.